Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis

Silverberg, Jonathan|||0000-0003-3686-7805; Bieber, Thomas|||0000-0002-8800-3817; Paller, A.S.; Beck, L.; Kamata, M.; Puig Sanz, Lluís|||0000-0001-6083-0952; Wiseman, M.; Ezzedine, K.; Irvine, A.D.; Foley, Peter; Del Rosso, J.; Gold, L.S.; Johansson, E.; Dossenbach, M.; Gallo, Gaia; Akmaz, B.; Casillas, M.; Karlsson, A.; Curteis, T.; Chovatiya, R.

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis

Introduction: A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic dermatitis in adults and adolescents. Methods: The NM...

Descripción completa

Detalles Bibliográficos
Autores:	Silverberg, Jonathan\|\|\|0000-0003-3686-7805, Bieber, Thomas\|\|\|0000-0002-8800-3817, Paller, A.S., Beck, L., Kamata, M., Puig Sanz, Lluís\|\|\|0000-0001-6083-0952, Wiseman, M., Ezzedine, K., Irvine, A.D., Foley, Peter, Del Rosso, J., Gold, L.S., Johansson, E., Dossenbach, M., Gallo, Gaia, Akmaz, B., Casillas, M., Karlsson, A., Curteis, T., Chovatiya, R.
Tipo de recurso:	artículo
Fecha de publicación:	2025
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:321779
Acceso en línea:	https://ddd.uab.cat/record/321779 https://dx.doi.org/urn:doi:10.1007/s13555-025-01357-7
Access Level:	acceso abierto
Palabra clave:	Atopic dermatitis Eczema Area and Severity Index Investigator Global Assessment Lebrikizumab Network meta-analysis Pruritus/itch Numeric Rating Scale

id	ES_3de3573ae32cdd048d7eabb5a0ccf9e1
oai_identifier_str	oai:ddd.uab.cat:321779
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic DermatitisNetwork Meta-analysis of EfficacySilverberg, Jonathan\|\|\|0000-0003-3686-7805Bieber, Thomas\|\|\|0000-0002-8800-3817Paller, A.S.Beck, L.Kamata, M.Puig Sanz, Lluís\|\|\|0000-0001-6083-0952Wiseman, M.Ezzedine, K.Irvine, A.D.Foley, PeterDel Rosso, J.Gold, L.S.Johansson, E.Dossenbach, M.Gallo, GaiaAkmaz, B.Casillas, M.Karlsson, A.Curteis, T.Chovatiya, R.Atopic dermatitisEczema Area and Severity IndexInvestigator Global AssessmentLebrikizumabNetwork meta-analysisPruritus/itch Numeric Rating ScaleIntroduction: A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic dermatitis in adults and adolescents. Methods: The NMA included randomized, double-blind, placebo-controlled monotherapy phase 2 and 3 trials of biologics (lebrikizumab 250 mg every 2 weeks [Q2W], dupilumab 300 mg Q2W, and tralokinumab 300 mg Q2W) and JAK inhibitors (abrocitinib 100/200 mg daily, baricitinib 2/4 mg daily, and upadacitinib 15/30 mg daily) at approved doses. Efficacy outcomes included the proportions of patients achieving Eczema Area and Severity Index (EASI) improvement, an Investigator Global Assessment of 0 or 1 (IGA 0/1), and a ≥ 4-point improvement in pruritus/itch numeric rating scale score at 12 weeks (abrocitinib) or 16 weeks (other treatments). Itch was also assessed at week 4. A Bayesian NMA employing baseline risk-adjusted random effects models was used to estimate treatment differences. Results: Twenty-two monotherapy studies involving 8531 patients were included in the NMA. By week 12/16, lebrikizumab had superior odds of achieving IGA 0/1 and itch improvement compared to baricitinib and tralokinumab; similar odds to dupilumab, abrocitinib, and upadacitinib 15 mg; and inferior odds to upadacitinib 30 mg. Additionally, lebrikizumab had a higher probability of improving EASI than baricitinib 2 mg; similar probability to baricitinib 4 mg, tralokinumab, dupilumab, abrocitinib, and upadacitinib 15 mg; and lower probability than upadacitinib 30 mg daily. At week 4, lebrikizumab had superior odds of improving itch compared to tralokinumab; similar odds to baricitinib, dupilumab, and abrocitinib 100 mg; and inferior odds to abrocitinib 200 mg and upadacitinib. Conclusion: Among biologics, lebrikizumab was comparable to dupilumab and superior to tralokinumab in improving response rates at week 16. Upadacitinib 30 mg was the only JAK inhibitor with superior response rates compared to lebrikizumab.Universitat Autònoma de Barcelona 22025-01-0120252025-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/321779https://dx.doi.org/urn:doi:10.1007/s13555-025-01357-7reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3217792026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis Network Meta-analysis of Efficacy
title	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis
spellingShingle	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis Silverberg, Jonathan\|\|\|0000-0003-3686-7805 Atopic dermatitis Eczema Area and Severity Index Investigator Global Assessment Lebrikizumab Network meta-analysis Pruritus/itch Numeric Rating Scale
title_short	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis
title_full	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis
title_fullStr	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis
title_full_unstemmed	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis
title_sort	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis
dc.creator.none.fl_str_mv	Silverberg, Jonathan\|\|\|0000-0003-3686-7805 Bieber, Thomas\|\|\|0000-0002-8800-3817 Paller, A.S. Beck, L. Kamata, M. Puig Sanz, Lluís\|\|\|0000-0001-6083-0952 Wiseman, M. Ezzedine, K. Irvine, A.D. Foley, Peter Del Rosso, J. Gold, L.S. Johansson, E. Dossenbach, M. Gallo, Gaia Akmaz, B. Casillas, M. Karlsson, A. Curteis, T. Chovatiya, R.
author	Silverberg, Jonathan\|\|\|0000-0003-3686-7805
author_facet	Silverberg, Jonathan\|\|\|0000-0003-3686-7805 Bieber, Thomas\|\|\|0000-0002-8800-3817 Paller, A.S. Beck, L. Kamata, M. Puig Sanz, Lluís\|\|\|0000-0001-6083-0952 Wiseman, M. Ezzedine, K. Irvine, A.D. Foley, Peter Del Rosso, J. Gold, L.S. Johansson, E. Dossenbach, M. Gallo, Gaia Akmaz, B. Casillas, M. Karlsson, A. Curteis, T. Chovatiya, R.
author_role	author
author2	Bieber, Thomas\|\|\|0000-0002-8800-3817 Paller, A.S. Beck, L. Kamata, M. Puig Sanz, Lluís\|\|\|0000-0001-6083-0952 Wiseman, M. Ezzedine, K. Irvine, A.D. Foley, Peter Del Rosso, J. Gold, L.S. Johansson, E. Dossenbach, M. Gallo, Gaia Akmaz, B. Casillas, M. Karlsson, A. Curteis, T. Chovatiya, R.
author2_role	author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv	Atopic dermatitis Eczema Area and Severity Index Investigator Global Assessment Lebrikizumab Network meta-analysis Pruritus/itch Numeric Rating Scale
topic	Atopic dermatitis Eczema Area and Severity Index Investigator Global Assessment Lebrikizumab Network meta-analysis Pruritus/itch Numeric Rating Scale
description	Introduction: A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic dermatitis in adults and adolescents. Methods: The NMA included randomized, double-blind, placebo-controlled monotherapy phase 2 and 3 trials of biologics (lebrikizumab 250 mg every 2 weeks [Q2W], dupilumab 300 mg Q2W, and tralokinumab 300 mg Q2W) and JAK inhibitors (abrocitinib 100/200 mg daily, baricitinib 2/4 mg daily, and upadacitinib 15/30 mg daily) at approved doses. Efficacy outcomes included the proportions of patients achieving Eczema Area and Severity Index (EASI) improvement, an Investigator Global Assessment of 0 or 1 (IGA 0/1), and a ≥ 4-point improvement in pruritus/itch numeric rating scale score at 12 weeks (abrocitinib) or 16 weeks (other treatments). Itch was also assessed at week 4. A Bayesian NMA employing baseline risk-adjusted random effects models was used to estimate treatment differences. Results: Twenty-two monotherapy studies involving 8531 patients were included in the NMA. By week 12/16, lebrikizumab had superior odds of achieving IGA 0/1 and itch improvement compared to baricitinib and tralokinumab; similar odds to dupilumab, abrocitinib, and upadacitinib 15 mg; and inferior odds to upadacitinib 30 mg. Additionally, lebrikizumab had a higher probability of improving EASI than baricitinib 2 mg; similar probability to baricitinib 4 mg, tralokinumab, dupilumab, abrocitinib, and upadacitinib 15 mg; and lower probability than upadacitinib 30 mg daily. At week 4, lebrikizumab had superior odds of improving itch compared to tralokinumab; similar odds to baricitinib, dupilumab, and abrocitinib 100 mg; and inferior odds to abrocitinib 200 mg and upadacitinib. Conclusion: Among biologics, lebrikizumab was comparable to dupilumab and superior to tralokinumab in improving response rates at week 16. Upadacitinib 30 mg was the only JAK inhibitor with superior response rates compared to lebrikizumab.
publishDate	2025
dc.date.none.fl_str_mv	2 2025-01-01 2025 2025-01-01
dc.type.none.fl_str_mv	Article de revisió http://purl.org/coar/resource_type/c_dcae04bc VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/321779 https://dx.doi.org/urn:doi:10.1007/s13555-025-01357-7
url	https://ddd.uab.cat/record/321779 https://dx.doi.org/urn:doi:10.1007/s13555-025-01357-7
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869406475926896640
score	15,811543

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis

Similares en LA Referencia